Long-term Outcome of TNF Alpha Therapy in IBD

Medical University of Graz

Status: Completed

Conditions: IBD

Treatments: Other: TNF Alpha therapy

Study type: Observational

Funder types: Other

Identifiers

NCT04575701

1465/2018

Details and patient eligibility

About

The aim of this retrospective study is to assess the outcome of patients with inflammatory bowel disease (IBD) under TNF-alpha antibody therapy over a period of 20 years

Full description

Long-term results published so far show that over the years a large part of patients have to stop TNF Alpha antibody therapy in IBD. Reasons are mostly loss of effectiveness or intolerance or side effects. Reasons for the termination are usually poorly characterized with regard to the exact reason and time. As a consequence, the aim of this retrospective study is to assess the outcome of patients with inflammatory bowel disease under TNF-alpha antibody therapy over a period of 20 years

Enrollment: 538 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a confirmed IBD diagnosis
• TNF Alpha antibody therapy in the last 20 years at our outpatient clinic

Exclusion criteria

• Not Meeting the inclusion criteria
• Lack of clinical data, no follow up available

Trial design

538 participants in 3 patient groups

Ulcerative Colitis (UC)

Description:

This Group includes all patients suffering from UC who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital.

Treatment:

Other: TNF Alpha therapy

Crohn's disease (CD)

Description:

This Group includes all patients suffering from CD who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital.

Treatment:

Other: TNF Alpha therapy

IBD unclassified

Description:

This Group includes all patients suffering from IBD unclassified who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital.

Treatment:

Other: TNF Alpha therapy